NPM1 mutation (35% vs. 27%), biallelic CEBPA mutations (14% vs. 4%), and driver mutations with no detected class-defining lesion (30% vs. 11%) were observed more commonly in our cohort than in prior genomic classifications, because such mutations were observed more frequently in NK AML and the population with NK AML fundamentally excluded cytogenetic abnormalities. The gene discussed is CEBPA; the disease is acute myeloid leukemia.